Clin2
NCT07467564Possibly a fitRecruiting

Does Dupilumab help anxiety and depression in eczema?

Atopic Dermatitis

Treatments studied

Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.

This study looks at whether Dupilumab (a treatment for moderate-to-severe eczema) can also help improve symptoms of anxiety and depression. It is for people with eczema who also have these mood symptoms and are about to start Dupilumab.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
184 people
Ages
12 years and older
Study type
Observational

Who can take part

  • You have moderate-to-severe eczema and also have signs of anxiety or depression.
  • Your doctor has decided you should start a medicine called Dupilumab (Dupixent) within 30 days of joining the study.
  • You have not taken any antidepressants or anti-anxiety medications in the last 6 months, and you won't be taking them during the study.
  • You are not pregnant, breastfeeding, or planning to become pregnant in the next 6 months.
  • You do not have serious infections (like HIV, hepatitis B or C), cancer, or other major illnesses.
  • You are not currently in any other clinical trial.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06192563Recruiting
Dupilumab for severe eczema with limited skin rash

This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.

Bologna
NCT05098821Recruiting
Study factors that affect eczema control on dupilumab

This trial studies why eczema (“atopic dermatitis”) varies in severity even when people receive the medicine dupilumab. It may help doctors better predict who responds well and how to monitor treatment.

Berlin
NCT05858619Recruiting· Phase 4
Study of skin response to dupilumab in eczema

This trial studies how the body’s “molecular signals” change in the skin after using dupilumab for eczema. It may help researchers understand who benefits most from treatment.

San Francisco, California
NCT05042258Recruiting· Phase 4
Dupilumab to improve sleep and itch in children with eczema

This trial studies whether dupilumab can improve daily body clock (circadian function), sleep, and itching in children with moderate-to-severe eczema that isn’t well controlled by creams. It may help kids who are having significant sleep trouble and ongoing itch.

Chicago, Illinois
NCT06039241Recruiting
Long-term Dupilumab treatment for atopic dermatitis

This study looks at how well Dupilumab works over time for people with atopic dermatitis (eczema). It includes adults, teens, and children ages 6 and up.

Aachen
NCT05268107Recruiting· Phase 4
Study dupilumab skin effects in different ethnic groups

This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.

Ann Arbor, Michigan

Hear when a new Atopic Dermatitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.